145 related articles for article (PubMed ID: 16762624)
21. A concise review of serum markers for hepatocellular cancer.
Wright LM; Kreikemeier JT; Fimmel CJ
Cancer Detect Prev; 2007; 31(1):35-44. PubMed ID: 17293059
[TBL] [Abstract][Full Text] [Related]
22. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma.
Chau GY; Lee AF; Tsay SH; Ke YR; Kao HL; Wong FH; Tsou AP; Chau YP
Histopathology; 2007 Aug; 51(2):204-18. PubMed ID: 17559540
[TBL] [Abstract][Full Text] [Related]
24. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.
Okamoto M; Utsunomiya T; Wakiyama S; Hashimoto M; Fukuzawa K; Ezaki T; Hanai T; Inoue H; Mori M
Ann Surg Oncol; 2006 Jul; 13(7):947-54. PubMed ID: 16788756
[TBL] [Abstract][Full Text] [Related]
25. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
[TBL] [Abstract][Full Text] [Related]
26. Melanoma antigen-1 mRNA combined with alpha-fetoprotein mRNA levels in peripheral blood of patients with hepatocellular carcinoma: a predictor of postoperative recurrence or metastasis?
Zhang Y; Song T; Meng L; Wu X; Ba Y; Li Q
ANZ J Surg; 2009; 79(1-2):62-9. PubMed ID: 19183381
[TBL] [Abstract][Full Text] [Related]
27. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
[TBL] [Abstract][Full Text] [Related]
28. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
29. [Screening hepatocellular carcinoma autoantibodies by serological proteome analysis].
Feng JT; Liu YK; Dai Z; Zhou HJ; Song HY; Qin LX; Jin H; Lu HJ; Tang ZY
Zhonghua Gan Zang Bing Za Zhi; 2005 Nov; 13(11):832-5. PubMed ID: 16313728
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
31. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
32. Proteomics for the early detection and treatment of hepatocellular carcinoma.
Feng JT; Shang S; Beretta L
Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
[TBL] [Abstract][Full Text] [Related]
33. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.
Ang IL; Poon TC; Lai PB; Chan AT; Ngai SM; Hui AY; Johnson PJ; Sung JJ
J Proteome Res; 2006 Oct; 5(10):2691-700. PubMed ID: 17022640
[TBL] [Abstract][Full Text] [Related]
34. Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma.
Wang HY
Methods Cell Biol; 2007; 82():689-707. PubMed ID: 17586277
[TBL] [Abstract][Full Text] [Related]
35. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma.
Kuboki S; Shimizu H; Mitsuhashi N; Kusashio K; Kimura F; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Miyazaki M
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e157-64. PubMed ID: 17931370
[TBL] [Abstract][Full Text] [Related]
36. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
37. Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma.
Wang K; Xu X; Nie Y; Dai L; Wang P; Zhang J
Cancer Lett; 2009 Aug; 281(2):144-50. PubMed ID: 19304375
[TBL] [Abstract][Full Text] [Related]
38. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer.
Peng XQ; Wang F; Geng X; Zhang WM
Expert Rev Proteomics; 2009 Oct; 6(5):551-61. PubMed ID: 19811076
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma.
Yang LY; Tao YM; Ou DP; Wang W; Chang ZG; Wu F
Clin Cancer Res; 2006 Oct; 12(19):5673-9. PubMed ID: 17020969
[TBL] [Abstract][Full Text] [Related]
40. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
Himoto T; Kuriyama S; Zhang JY; Chan EK; Kimura Y; Masaki T; Uchida N; Nishioka M; Tan EM
Int J Oncol; 2005 Oct; 27(4):1079-85. PubMed ID: 16142326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
